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The artiﬁcial ascites technique is often used during radiofrequency ablation (RFA) for hepatocellular 
carcinoma (HCC) treatment because it prevents visceral damage and improves visualization by mini-
mizing interference of the lungs and mesentery.  This study determined the eﬃcacy and safety of RFA 
using the artiﬁcial ascites technique in HCC patients.  We examined 188 HCC patients who were treated 
by RFA and fulﬁlled the Milan criteria.  Treatment outcomes (complete ablation rate,  local recurrence 
rate,  complication rate,  liver function including total bilirubin level,  alanine aminotransferase level,  
albumin level,  and prothrombin time) were compared among patients divided into 3 groups based on 
the volume of artiﬁcial ascites injected: GroupⅠ (n＝86),  no artiﬁcial ascites injected; GroupⅡ (n＝
35),  ＜1,000ml artiﬁcial ascites injected; and Group Ⅲ (n＝67),  ＞1,000ml artiﬁcial ascites injected.  No 
signiﬁcant diﬀerence was observed in complete ablation or local recurrence rates among the 3 groups,  
or in the extent of liver function damage after RFA.  Artiﬁcial ascites disappeared within 7 days;  
additional diuretics were needed only in 5 (all from Group Ⅲ) of 102 patients.  No serious complica-
tions such as intestinal perforation or intraperitoneal bleeding were observed.  Thus,  we found that 
artiﬁcial ascites injection during RFA is eﬀective and safe,  and can be used to prevent major proce-
dural complications.
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adiofrequency ablation (RFA) is widely used as 
the main line of treatment for hepatocellular 
carcinoma (HCC) [1-3].  Numerous reports have been 
published on the eﬃcacy and complications of RFA 
[4-10].  Conventional RFA cannot be performed for 
certain conditions such as subdiaphragmatic tumors 
because the nodules are diﬃcult to visualize by ultra-
sonography.  In these cases,  the treatment of choice 
would be artiﬁcial pleural eﬀusion or the artiﬁcial 
ascites technique [11-15].  In addition,  conventional 
RFA is not feasible in cases where the tumor is adja-
cent to other vital organs because of the risk of caus-
ing burns to these organs; the artiﬁcial ascites tech-
nique is also useful in such cases [11-15].  The 
artiﬁcial ascites technique has advantages over the 
artiﬁcial pleural eﬀusion technique because it also 
avoids interference of the lungs and digestive tract at 
the same time.  Several reports exist on the artiﬁcial 
ascites technique as well as its safety and usefulness;  
however,  no report has described the inﬂuence of the 
technique on liver function parameters and diuretic use 
for post-operative control of induced artiﬁcial ascites 
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or pleural eﬀusion [14-16].  In this study,  we evalu-
ated changes in liver function parameters and the 
volume of residual ascites or pleural eﬀusion following 
artiﬁcial induction in HCC patients who were under-
going RFA.  Furthermore,  we determined the eﬃcacy,  
utility,  and safety of this technique.
Patients and Methods
　 Patients. A total of 257 patients underwent 
RFA in our institution between January 2006 and 
March 2009.  Among these,  188 HCC patients who 
fulﬁlled the Milan criteria and were classiﬁed as 
Child-Pugh A or B were analyzed retrospectively.  
Patients who received diuretics before RFA or who 
were classiﬁed as Child-Pugh C were excluded (Table 1),  
but were analyzed retrospectively.  The mean tumor 
size was 20±6mm (range,  10-30mm),  the mean tumor 
number per liver was 2.2±1.6 (range,  1-3),  and mean 
number of treatment sessions was 1.4±0.5.  Patients 
were classiﬁed into 3 groups according to the volume 
of artiﬁcial ascites injected: GroupⅠ,  no artiﬁcial 
ascites injected; GroupⅡ,  ＜1,000ml artiﬁcial ascites 
injected; and GroupⅢ,  ＞1,000ml artiﬁcial ascites 
injected.  We set the cut-oﬀ value at 1,000ml because 
that volume was close to the median.
　 Indications for the artiﬁcial ascites tech-
nique. We used the artiﬁcial ascites technique in 
the following cases: (1) failure to detect a nodule by 
usual ultrasonography because of tumor location (e.g.,  
below the diaphragm or left edge of the left lobe); (2) 
inability to perform RFA by the usual method because 
of proximity of the tumor to other vital organs (e.g.,  
digestive tract or heart); and (3) lack of clarity in the 
ultrasonographic image because of mesenteric inter-
ference.  In GroupⅡ,  22 patients (62.9ｵ) received 
artiﬁcial ascites based on reason (1),  7 patients (20.0ｵ) 
received artiﬁcial ascites based on reasons (2) or (3),  
and 6 patients (17.1ｵ) received artiﬁcial ascites based 
on reasons (1) (2),  and (3).  In GroupⅢ,  34 patients 
(50.8ｵ) received artiﬁcial ascites based on reason 
(1),  20 patients (29.9ｵ) received artiﬁcial ascites 
based on reason (2) or (3),  and 13 patients (19.4ｵ) 
received artiﬁcial ascites based on reasons (1),  (2) 
and (3).
　 Method of inducing artiﬁcial ascites. The 
breath-tuning method was used to induce artiﬁcial 
ascites.  Following administration of local anesthesia 
to the skin and liver surface,  the liver surface was 
penetrated (2mm deep) using a venula needle (TOP,  
Japan) at the point of maximum inspiration.  The nee-
dleʼs outer sheath was introduced immediately after 
the beginning of expiration.  The needle tip was with-
drawn from the liver at expiration,  and the sheath was 
inserted between the liver and parietal peritoneum.  
Once the sheath was in place,  500-3,000ml of 5ｵ 
glucose was injected into the peritoneal space to 
induce ascites (Fig.  1).
　 Volume of injected ascites. We injected 
artiﬁcial ascites until ultrasonographic visualization 
was suﬃcient or until a clear separation between tar-
get nodules and vital organs was obtained,  based on 
the reason for using artiﬁcial ascites.  The minimum 
injected volume was 500ml,  and the maximum injected 
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Table 1　 Characteristics of HCC patients treated by RFA.  Complete ablation and local recurrence rates among the 3 groups
Group Ⅰ Ⅱ Ⅲ
p value
Artiﬁcial ascites 0 ＜1,000ml ＞1,000ml
Case (male/female) 86 (71/15) 35 (29/6) 67 (57/10) p＝0.91
Age (years) 64 (37-87) 64 (47-78) 68 (47-73) p＝0.83
Tumor size (mm) 20 (10-30) 20 (10-30) 20 (10-30) p＝0.60
Number of treatment sessions 1 (1-3) 1 (1-2) 1 (1-3) p＝0.09
Virus HBV/HCV/NBNC 19/62/5 5/28/2 16/46/5 p＝0.80
Prothrombin time (%) 69 (48-102) 85 (37-98) 76 (50-91) p＝0.88
Albumin (g/dl) 3.3 (1.9-4.6) 3.5 (2.6-4.1) 3.3 (2.2-4.7) p＝0.50
Total bilirubin (mg/dl) 0.9 (0.3-3.2) 1.2 (0.4-2.3) 0.9 (0.3-2.5) p＝0.36
Complete ablation rate (%) 86/86 (100) 35/35 (100) 67/67 (100) －
Local recurrence rate (%) 4/86 (4.7) 2/35 (5.7) 3/67 (4.5) p＝0.96
Values indicate the median (range) unless otherwise noted.
volume for optimal visualization was 2,000ml.
　 RFA procedure and post-procedural follow-
up. Percutaneous RFA was performed under 
ultrasonographic guidance using an internally cooled 
single electrode with a 200-W generator (Cool-tip,  
Valleylab,  CO,  USA).  All patients were treated 
under conscious sedation with an intravenous injection 
of 15mg pentazocine hydrochloride (Astellas Pharma,  
USA).  The area from the skin to the liver capsule was 
anesthetized with 5-10ml 1ｵ lidocaine along the 
insertion route.  If patients complained of intolerable 
pain during ablation,  an additional 15mg of pentazo-
cine hydrochloride was administered intravenously.
　 We used 1- and 2-cm-long exposed metallic tip 
needles for tumors up to 1cm and from 1 to 2cm in 
diameter,  respectively.  A 3-cm-long exposed needle 
was used for tumors larger than 2cm.
　 Following tumor ablation,  we performed tract 
ablation during needle withdrawal to avoid peritoneal 
bleeding,  which was evaluated after the procedure by 
Doppler ultrasonography.  In case of persistent bleed-
ing,  the bleeding point at the surface of the liver was 
ablated using a 1-cm-long exposed needle.  Contrast-
enhanced computed tomography (CT) to evaluate the 
ablated area was performed 1-2 days after RFA.  We 
completed the treatment series when HCC was ablated 
with a radial margin of 5mm for curative purpose and 
without a margin for palliative purpose,  and we 
deﬁned both of them as complete ablation.  We did not 
drain the injected artiﬁcial ascites.  The injected 
artiﬁcial ascites generally moved from the abdominal 
cavity to the thoracic cavity because of negative pres-
sure in the latter.  In case of persistent ascites or 
pleural eﬀusion on follow-up CT,  we re-evaluated each 
patient 2 days after the procedure.  Additional diuret-
ics were administered if residual ascites or pleural 
eﬀusion was conﬁrmed,  because such patients would 
have suﬀered too long with abdominal distension and 
chest dullness.  Ultrasonography was performed 3 days 
after diuretic administration,  and the volume of 
residual ascites was again evaluated.  Diuretics were 
administered until complete elimination of residual 
ascites or pleural eﬀusion.
　 Laboratory tests were performed on the day before 
and 1 day after RFA [total bilirubin (TB) level;  
alanine aminotransferase (ALT) level; albumin (Alb) 
level; and prothrombin time (PT)].  Follow-up CT or 
ultrasonography and tests for tumor markers were 
performed at maximum intervals of 3 months.  Local 
recurrence was deﬁned as a recurrent tumor that 
touched the ablated area,  as identiﬁed by contrast-
enhanced CT.  Recurrence was evaluated 1 year after 
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Fig. 1　 Artiﬁcial ascites and RFA.  A,  Intercostal oblique ultrasonogram in the planning stage shows a subtle hypoechoic nodule only on 
deep inhalation; B,  Ultrasonogram in the RFA targeting stage following artiﬁcial ascites induction shows the index tumor more clearly,  
even on shallow breathing.  Note the radiofrequency electrode in the index tumor; C,  Ultrasonogram taken at the RFA monitoring stage.  
Note that a hyperechoic RFA zone can be observed.
RFA.  Treatment was promptly repeated in patients 
with conﬁrmed recurrence.
　 Statistical analysis. Diﬀerences in patient 
parameters were analyzed by ANOVA or Fisherʼs 
exact test.  Local recurrence at 1 year after RFA was 
evaluated by chi-square test.  Changes in laboratory 
parameters (TB,  ALT,  and Alb levels and PT) were 
analyzed by paired Studentʼs t-test.  The ratio of 
diuretics to artiﬁcial ascites volume was evaluated by 
the chi-square test.  A value of p＜0.05 was consid-
ered signiﬁcant.  StatView version 5.0 software 
(Hulinks,  Tokyo,  Japan) was used for statistical 
analysis.
Results
　 Diﬀerence in patient parameters. The arti-
ﬁcial ascites technique was attempted in 102 patients.  
We were unable to perform the technique in 3 patients 
because of mesenteric adhesions; these patients were 
treated by induction of artiﬁcial pleural eﬀusion and 
excluded from further analyses.  Consequently,  GroupⅠ 
had 86 patients (45.7ｵ),  GroupⅡ had 35 patients 
(18.6ｵ),  and GroupⅢ had 67 patients (35.6ｵ).  The 
success rate for artiﬁcial ascites induction was 97.1ｵ.  
No signiﬁcant diﬀerences were observed in this rate 
with respect to age,  tumor size,  or number of treat-
ment sessions.  Furthermore,  no signiﬁcant diﬀerence 
was observed in the complete ablation rate among the 
3 groups (Table 1).
　 Complications. No severe complications such 
as peritoneal bleeding,  intestinal perforation,  liver 
abscess,  liver infarction,  pneumothorax,  biliary tract 
injury,  skin burns,  lung burns,  uncontrolled ascites,  
or uncontrolled pleural eﬀusion were observed.  
However,  a few mild complications were observed.  
We observed 1 patient with transient hypotension,  1 
with hemothorax,  1 with hemobilia,  and 1 with rup-
tured esophageal varices; all these patients belonged 
to GroupⅠ.
　 The ALT level increased and PT decreased after 
RFA in all groups,  and no signiﬁcant diﬀerence was 
observed among the 3 groups.  TB increased slightly 
only in GroupⅡ patients (0.96-1.06mg/dl) (Fig.  2).  
No signiﬁcant diﬀerences were observed in Alb levels 
before and after RFA among the 3 groups.
　 Only 5 GroupⅢ patients (7.5ｵ) needed additional 
diuretics; GroupⅠ and Ⅱ patients did not require 
diuretics (Table 2).  In addition,  no relationship was 
observed between Child-Pugh classiﬁcation and diuretic 
use in GroupⅢ patients; diuretics were used in 5.5ｵ 
of Child-Pugh A patients and 16.7ｵ of Child-Pugh B 
patients (Table 3).  Regardless,  in all cases,  ascites 
were eliminated 1 week after RFA.
　 Local recurrence. Complete ablation was 
conﬁrmed by contrast-enhanced CT in all patients.  No 
signiﬁcant diﬀerence was observed in local recurrence 
rates at 1 year (p＝0.96).  The rates were as follows:  
4.7ｵ in GroupⅠ,  5.7ｵ in GroupⅡ,  and 4.5ｵ in 
GroupⅢ.  Patients in these groups were all retreated 
by RFA at the time of recurrence.
Discussion
　 RFA has widespread use in HCC treatment because 
of its eﬀectiveness and safety.  However,  complica-
tions (burns) can occur if vital organs such as the 
digestive tract,  gallbladder,  or bile duct are adjacent 
to ablation sites [6-9].  Subdiaphragmatic HCCs are 
diﬃcult to detect,  and the RFA needle may puncture 
the lungs during inspiration,  causing pneumothorax.  
In our earlier experiences with liver RFA without 
using the artiﬁcial ascites technique,  severe complica-
tions occurred in 7 patients (0.7ｵ),  including hemo-
thorax (n＝3),  pneumothorax (n＝1),  lung burn (n＝1),  
gastric penetration (n＝1),  and subphrenic abscess 
(n＝1).
　 The artiﬁcial pleural eﬀusion technique,  which is 
easier than the artiﬁcial ascites technique,  is used in 
many institutions to prevent lung obstruction and avoid 
complications [11-13].  However,  the results of our 
study indicated that the artiﬁcial ascites technique 
might be superior for the following reasons: (1) RFA 
for subdiaphragmatic HCCs and tumors adjacent to 
other vital organs can be performed,  (2) diaphrag-
matic injury can be prevented by pooling ascites 
between the liver and diaphragm,  (3) a clearer image 
can be obtained by ultrasonography because artiﬁcial 
ascites ﬁll the gaps between organs (e.g.,  between the 
mesentery and liver or between the intestine and 
liver),  and (4) RFA can be performed with patients in 
a supine position so that virtual ultrasonography can 
be used,  which synchronizes ultrasonography images 
with those of CT [17,  18].
　 We achieved a high complete ablation rate because 
artiﬁcial ascites eliminated the diﬃculties of ablation,  
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as reported by Song et al. [14].  As a result,  the local 
recurrence rate was low (4.9ｵ) in our study patients;  
this rate was not signiﬁcantly diﬀerent from that in 
patients who underwent RFA without artiﬁcial ascites 
(4.7ｵ).
　 It is possible that artiﬁcial ascites could deterio-
rate liver function because of impaired portal blood 
ﬂow from the excessive water load in the abdominal 
cavity,  particularly in Child-Pugh B cirrhosis patients.  
Alb,  TB,  and ALT levels and PT were slightly 
altered the day after RFA,  but not in a manner that 
would compromise the safety of the procedure.  
Furthermore,  residual ascites usually disappeared 
spontaneously without diuretics; cases requiring post-
procedural diuretics were few (6.6ｵ).  These ﬁndings 
indicated that performing RFA is safe even with a 
large volume of artiﬁcial ascites and that injecting 
artiﬁcial ascites is safe until tumors are clearly visu-
alized or until the distance between the lesion and 
neighboring internal organs is suﬃciently less so as to 
perform ablation,  although we limited the volume to 
2,000ml.
　 A problem unique to the artiﬁcial ascites technique 
is the possibility of bleeding from the puncture site on 
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Fig. 2　 Change in liver function parameters before and after RFA in each group.  Comparison of laboratory parameters before and after 
RFA.  The ALT level increased and prothrombin time (PT) decreased after RFA in all groups,  and no signiﬁcant diﬀerence was observed 
among the 3 groups.  The TB level increased slightly only in GroupⅡ patients (0.96-1.06mg/dl).  No signiﬁcant diﬀerence in Alb levels 
before and after RFA was observed in any of the 3 groups.
Table 2　 Additional diuretics after RFA among the 3 groups
Group Ⅰ Ⅱ Ⅲ
Additional diuretics 0/86 (0) 0/35 (0) 5/67 (7.5) p＝0.0097
(　): %
Table 3　 Additional diuretics after RFA according to the Child-
Pugh classiﬁcation in Group Ⅲ patients
Child-Pugh classiﬁcation A B
Additional diuretics 3/55 (5.5) 2/12 (16.7) p＝0.32
(　): %
the liver surface; however,  this bleeding is control-
lable.  When bleeding was suspected by Doppler 
ultrasonography,  it was easily controlled by an addi-
tional brief ablation of the site.
　 We performed RFA using the artiﬁcial ascites 
technique in 50ｵ of our patients to avoid any con-
cerns of complications that could occur otherwise.  
Furthermore,  artiﬁcial ascites induction was easily 
performed by the breath-tuning method.  The success 
rate of induction (97.1ｵ) reported here is equal to or 
much higher than that reported in other studies (88-
100ｵ) [14-16].  Although experience to master this 
artiﬁcial ascites technique must be gained under the 
guidance of a skilled mentor,  the technique is worth 
employing.
　 Failure to induce artiﬁcial ascites because of adhe-
sions was an important issue,  although this condition 
is infrequent.  The pleural eﬀusion technique was used 
in some patients with a history of abdominal surgery 
because of severe mesenteric adhesions.  The beneﬁts 
of the artiﬁcial ascites technique were not attainable 
for these patients,  and laparoscopic or surgical treat-
ments are occasionally necessary in such patients 
[16].
　 Although further research is required to resolve a 
few of the aforementioned issues,  and a prospective 
study is needed to conﬁrm our data,  we conclude that 
artiﬁcial ascites induction is a safe and useful tech-
nique to prevent RFA-associated complications and 
improve ultrasonographic visualization.
References
 1. Rossi S,  Di Stasi M,  Buscarini E,  Quaretti P,  Garbagnati F,  
Squassante L,  Paties CT,  Silverman DE and Buscarini L:  
Percutaneous RF interstitial thermal ablation in the treatment of 
hepatic cancer.  Am J Roentgenol (1996) 167: 759-768.
 2. Rossi S,  Garbagnati F,  Rosa L,  Azzaretti A,  Belloni G and 
Quaretti P: Radiofrequency thermal ablation for treatment of hepa-
tocellular carcinoma.  Int J Clin Oncol (2002) 7: 225-235.
 3. Shiina S,  Teratani T,  Obi S,  Hamamura K,  Koike Y and Omata M:  
Nonsurgical treatment of hepatocellular carcinoma: from percuta-
neous ethanol injection therapy and percutaneous microwave 
coagulation therapy to radiofrequency ablation.  Oncology (2002) 
62 Suppl 1: 64-68.
 4. Livraghi T,  Goldberg SN,  Lazzaroni S,  Meloni F,  Solbiati L and 
Gazelle GS: Small hepatocellular carcinoma: treatment with radio-
frequency ablation versus ethanol injection.  Radiology (1999) 210:  
655-661.
 5. Shibata T,  Iimuro Y,  Yamamoto Y,  Maetani Y,  Ametani F,  Itoh K 
and Konishi J: Small hepatocellular carcinoma: comparison of 
radiofrequency ablation and percutaneous microwave coagulation 
therapy.  Radiology (2002) 223: 331-337.
 6. Mulier S,  Mulier P,  Ni Y,  Miao Y,  Dupas B,  Marchal G,  De 
Wever I and Michel L: Complications of radiofrequency coagula-
tion of liver tumors.  Br J Surg (2002) 89: 1206-1222.
 7. Livraghi T,  Solbiati L,  Meloni MF,  Gazelle GS,  Halpern EF and 
Goldberg SN: Treatment of focal liver tumors with percutaneous 
radio-frequency ablation: Complications encountered in a multi-
center study.  Radiology (2003) 226: 441-451.
 8. Yamamoto T,  Kubo S,  Hirohashi K,  Tanaka S,  Uenishi T,  Ogawa 
M,  Sakabe K,  Hai S,  Yamamoto S,  Shuto T,  Tanaka H and 
Kinoshita H: Secondary hemocholecyst after radiofrequency abla-
tion therapy for hepatocellular carcinoma.  J Gastroenterol (2003) 
38: 399-403.
 9. Scaife CL and Curley SA: Complication,  local recurrence,  and 
survival rates after radiofrequency ablation for hepatic malignan-
cies.  Surg Oncol Clin N Am (2003) 12: 243-255.
10. Ogawa T,  Kawamoto H,  Kobayashi Y,  Nakamura S,  Miyatake H,  
Harada R,  Tsutsumi K,  Fujii M,  Kurihara N,  Kato H,  Hirao K,  
Mizuno O,  Ishida E,  Okada H and Yamamoto K: Prevention of bil-
iary complication in radiofrequency ablation for hepatocellular car-
cinoma－Cooling eﬀect by endoscopic nasobiliary drainage tube.  
Eur J Radiol.  (2010) 73: 385-390.
11. Minami Y,  Kudo M,  Kawasaki T,  Chung H,  Ogawa C,  Inoue T,  
Sakaguchi Y,  Sakamoto H and Shiozaki H: Percutaneous ultra-
sound-guided radiofrequency ablation with artiﬁcial pleural eﬀusion 
for hepatocellular carcinoma in the hepatic dome.  J Gastroenterol 
(2003) 38: 1066-1070.
12. Koda M,  Ueki M,  Maeda Y,  Mimura K,  Okamoto K,  Matsunaga Y,  
Kawakami M,  Hosho K and Murawaki Y: Percutaneous sono-
graphicially guided radiofrequency ablation with artiﬁcial pleural 
eﬀusion for hepatocellular carcinoma located under the diaphragm.  
AJR Am J Roentgenol (2004) 183: 583-588.
13. Fukuno H,  Tamaki K,  Urata M,  Kohno N,  Shimizu I,  Nomura M,  
Ito S and Saito K: Inﬂuence of an artiﬁcial pleural eﬀusion tech-
nique on cardio-pulmonary function and autonomic activity.  J Med 
Invest (2007) 54: 48-53.
14. Song I,  Rhim H,  Lim HK,  Kim YS and Choi D: Percutaneous 
radiofrequency ablation of hepatocellular carcinoma abutting the 
diaphragm and gastrointestinal tracts with the use of artiﬁcial 
ascites: safety and technical eﬃcacy in 143 patients.  Eur Radiol 
(2009) 19: 2630-2640.
15. Rhim H,  Lim HK,  Kim YS and Choi D: Percutaneous radiofre-
quency ablation with artiﬁcial ascites for hepatocellular carcinoma 
in the hepatic dome: Initial Experience.  Am J Roentgenol (2008) 
190: 91-98.
16. Hirooka M,  Kisaka Y,  Uehara T,  Ishida K,  Kumagi T,  Watanabe Y,  
Abe M,  Matsuura B,  Hiasa Y and Onji M: Eﬃcacy of laparoscopic 
radiofrequency ablation for hepatocellular carcinoma compared to 
percutaneous radiofrequency ablation with artiﬁcial ascites.  Dig 
Endosc (2009) 21: 82-86.
17. Toyoda M,  Kakizaki S,  Horiuchi K,  Katakai K,  Sohara N,  Sato K,  
Takagi H,  Mori M and Nakajima T: Computed tomography-guided 
transpulmonary radiofrequency ablation for hepatocellular carci-
noma located in hepatic dome.  World J Gastroenterol (2006) 12:  
608-611.
18. Kitada T,  Murakami T,  Kuzushita N,  Minamitani K,  Nakajo K,  
Osuga K,  Miyoshi E,  Nakamura H,  Kishino B,  Tamura S and 
Hayashi N: Eﬀectiveness of real-time virtual sonography-guided 
radiofrequency ablation treatment for patients with hepatocellular 
carcinomas.  Hepatol Res (2008) 38: 565-571.
284 Acta Med.  Okayama　Vol.  66,  No.  3Nishimura et al.
